公开(公告)号：US20040037816A1

公开(公告)日：2004-02-26

申请号：US10419039

申请日：2003-04-18

Applicant: Monash University

Inventor： Richard Boyd

IPC: A61K048/00 ,  A61K038/09

CPC classification number: A61K39/39 ,  A61K31/167 ,  A61K31/4178 ,  A61K31/4439 ,  A61K35/28 ,  A61K35/36 ,  A61K38/08 ,  A61K38/09 ,  A61K38/1825 ,  A61K38/19 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/2046 ,  A61K38/2086 ,  A61K39/0008 ,  A61K39/001 ,  A61K48/00 ,  A61K2300/00

Abstract: The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue and/or cells. By reactivating the recipient's thymus and providing hematopoietic stem cells from the donor, the previously nullforeignnull matter becomes recognized as nullselfnull in the recipient and is not rejected. The patient's T cell population is depleted. In some embodiments, the hematopoietic stem cells are CD34null. The recipient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In some embodiments, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.

公开(公告)号：US06632424B1

公开(公告)日：2003-10-14

申请号：US08444626

申请日：1995-05-19

Applicant: Stewart D. Lyman ,  Patricia M. Beckmann

Inventor： Stewart D. Lyman ,  Patricia M. Beckmann

IPC: C07K1452

CPC classification number: C12N5/0647 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/025 ,  A01K2267/03 ,  A01K2267/0331 ,  A01K2267/0381 ,  A61K38/00 ,  A61K38/193 ,  A61K38/202 ,  A61K38/2046 ,  A61K48/00 ,  C07K14/475 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/75 ,  C12N15/8509 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/26 ,  C12N2510/00 ,  A61K2300/00

Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3 -L finds use in treating patients with anemia, AIDS and various cancers.

Abstract translation: 公开了能够转导自我更新信号以调节祖细胞和干细胞的生长，增殖或分化的flt3受体的配体。 本发明涉及作为分离蛋白质的flt3-L，编码flt3-L的DNA，编码flt3-L的cDNA转染的宿主细胞，包含flt3-L的组合物，使用flt3-L改善哺乳动物的基因转移的方法， 以及使用flt3-L改善移植的方法。 Flt3 -L可用于治疗贫血，艾滋病和各种癌症患者

公开(公告)号：US20020177571A1

公开(公告)日：2002-11-28

申请号：US09997525

申请日：2001-11-29

Inventor： Erlinda M. Gordon ,  Frederick L. Hall

IPC: A61K048/00 ,  C12N015/867

CPC classification number: A61K47/4813 ,  A61K38/1709 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2006 ,  A61K38/2013 ,  A61K38/2046 ,  A61K38/217 ,  A61K47/555 ,  A61K48/00 ,  C12N15/86 ,  C12N2740/13043 ,  C12N2740/13045 ,  C12N2810/857

Abstract: This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.

Abstract translation: 本发明提供了治疗癌症的组合物和方法。 更具体地，本发明涉及包含细胞因子基因的靶向的逆转录病毒载体，其可以单独施用或与包含用于治疗受试者中的癌症的杀细胞基因的靶向逆转录病毒载体组合施用。 还提供了包含用于所述方法的组合物的试剂盒或药物递送系统。

公开(公告)号：US20020127201A1

公开(公告)日：2002-09-12

申请号：US10141199

申请日：2002-05-07

Applicant: Dana-Farber Cancer Institute.

Inventor： Vassiliki A. Boussiotis ,  Lee M. Nadler

IPC: A61K039/395 ,  A61K039/02 ,  A61K039/12 ,  A61K039/00 ,  A61K038/20

CPC classification number: C07K14/7155 ,  A61K38/2026 ,  A61K38/2046 ,  A61K38/2086 ,  C07K14/715 ,  C07K16/244 ,  C07K16/2866 ,  G01N33/6869

Abstract: When stimulated through the T cell receptor(TCR)/CD3 complex without requisite costimulation through the CD28/B7 interaction, T cells enter a state of antigen specific unresponsiveness or anergy. This invention is based, at least in part, on the discovery that signaling though a common cytokine receptor null chain (e.g., interleukin-2 receptor, interleukin-4 receptor, interleukin-7 receptor, interleukin-15 receptor) prevents the induction of T cell anergy. This null chain has been found to be associated with a JAK3 kinase having a molecular weight of about 116 kD (as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis) and signaling through the null chain induces phosphorylation of the JAK3 kinase. Accordingly, methods for stimulating or inhibiting proliferation by a T cell which expresses a cytokine receptor null chain are disclosed.

Abstract translation: 当通过CD28 / B7相互作用刺激通过T细胞受体（TCR）/ CD3复合物而没有必要的共刺激时，T细胞进入抗原特异性无反应或无反应的状态。 本发明至少部分地基于以下发现，即通过常见的细胞因子受体γ链（例如白细胞介素-2受体，白介素-4受体，白细胞介素-7受体，白细胞介素-15受体）的信号传导阻止T的诱导 细胞无反应。 已经发现该γ链与具有约116kD分子量（通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳测定）的JAK3激酶相关，并且通过γ链的信号传导诱导JAK3激酶的磷酸化。 因此，公开了用于刺激或抑制表达细胞因子受体γ链的T细胞增殖的方法。

公开(公告)号：US12016902B2

公开(公告)日：2024-06-25

申请号：US16500194

申请日：2018-04-04

Applicant: LOMA LINDA UNIVERSITY

Inventor： Kimberly J. Payne ,  Olivia L. Francis-Boyle

IPC: A61K38/20 ,  A61K38/19 ,  A61P35/00 ,  A61P35/02 ,  G01N33/574 ,  A61K38/18 ,  A61K45/06

CPC classification number: A61K38/2046 ,  A61K38/19 ,  A61P35/00 ,  A61P35/02 ,  G01N33/57426 ,  G01N33/57492 ,  A61K38/1808 ,  A61K45/06 ,  G01N33/57411 ,  G01N33/57423 ,  G01N33/57449

Abstract: In one aspect, methods of treating a subject having a cancer that expresses a cytokine receptor are provided. In some embodiments, the method comprises administering to the subject a biologic agent in an amount sufficient to induce loss of cytokine receptor signaling through increased expression of a Suppressor of Cytokine Signaling genes and/or loss of one or more cytokine receptor components from the cancer cell surface. In some embodiments, the biologic agent is a cytokine or cytokine mimetic.

公开(公告)号：US11999771B2

公开(公告)日：2024-06-04

申请号：US18061567

申请日：2022-12-05

Applicant: MEDIKINE, INC.

Inventor： William J. Dower ,  Ronald W. Barrett ,  Michael C. Needels ,  Steven E. Cwirla ,  Alice V. Bakker ,  Inkyung Park

IPC: C07K14/54 ,  A61K38/20 ,  A61K38/00 ,  C07K7/08 ,  C07K14/715

CPC classification number: C07K14/5418 ,  A61K38/2046 ,  A61K38/00 ,  C07K7/08 ,  C07K14/7155 ,  C07K2319/30

Abstract: IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are disclosed. The IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins are IL-7R agonists.

公开(公告)号：US20230279069A1

公开(公告)日：2023-09-07

申请号：US18053671

申请日：2022-11-08

Applicant: Genexine, Inc.

Inventor： Donghoon CHOI ,  Changyong Eun ,  Seong Hoon Jeong ,  Jun Yeul LIM

IPC: C07K14/54 ,  A61K47/26 ,  A61K9/08 ,  A61K47/12 ,  A61K47/10 ,  A61K47/18 ,  C07K7/06 ,  A61K38/20

CPC classification number: C07K14/5418 ,  A61K9/08 ,  A61K38/2046 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C07K7/06 ,  C07K14/54 ,  C07K5/081 ,  C07K2319/30

Abstract: Provided is a pharmaceutical formulation comprising a modified IL-7 protein. More particularly, it comprises (a) a modified IL-7 fusion protein; (b) a basal buffer with a concentration of 10 to 50 mM; (c) a sugar with a concentration of 2.5 to 5 w/v%; and (d) a surfactant with a concentration of 0.05 to 6 w/v%.
Such pharmaceutical formulation of a modified IL-7 fusion protein does not show aggregates formation, but shows protective effects on proteins under stress conditions such as oxidation or agitation, and thus can effectively be used for the treatment of a patient.

公开(公告)号：US20230256057A1

公开(公告)日：2023-08-17

申请号：US18015820

申请日：2021-07-13

Applicant: Transgene

Inventor： Geneviève INCHAUSPE ,  Perrine MARTIN ,  Stéphane LEUNG-THEUNG-LONG ,  Karine LELU-SANTOLARIA ,  Alexei EVLACHEV ,  Charles Antoine COUPET ,  Aurélie RAY ,  Clarisse DUBOIS

IPC: A61K38/20 ,  A61K48/00 ,  A61P37/04 ,  C12N15/86

CPC classification number: A61K38/2046 ,  A61K48/0041 ,  A61P37/04 ,  C12N15/86 ,  C12N2710/24143 ,  C12N2710/24162

Abstract: The present invention is in the field of immunotherapy. The invention provides non-propagative viral vectors comprising a nucleic acid molecule encoding at least a polypeptide having an IL-7 activity, wherein said non-propagative viral vector is for use in the treatment of immune depression induced by sepsis, burn, trauma, major surgery, senescence and/or coronavirus.

公开(公告)号：US20190216898A1

公开(公告)日：2019-07-18

申请号：US16099280

申请日：2017-05-05

Applicant: Mulin WANG ,  Huanhuan FENG

Inventor： Mulin WANG ,  Huanhuan FENG ,  Zhenying ZHNAG ,  Linchong WANG ,  Xudong ZHU

IPC: A61K38/20 ,  A61P35/00 ,  C12N15/62 ,  C12N15/86 ,  A61K47/65 ,  A61K35/76

CPC classification number: A61K38/2086 ,  A61K35/76 ,  A61K38/20 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2046 ,  A61K38/206 ,  A61K47/65 ,  A61P35/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/62 ,  C12N15/85 ,  C12N15/86 ,  C12N15/861 ,  C12N15/864 ,  C12N15/867

Abstract: Disclosed are an interleukin combination or fusion proteins for preventing and/or treating malignant tumors, and various products prepared with same and the use thereof.

公开(公告)号：US20180353573A1

公开(公告)日：2018-12-13

申请号：US15777437

申请日：2016-11-30

Applicant: GENEXINE, INC.

Inventor： Moon Cheol KANG ,  Young Woo CHOI ,  Donghoon CHOI ,  Young Chul SUNG

IPC: A61K38/20 ,  A61K9/00 ,  A61P31/16 ,  A61P11/00

CPC classification number: A61K38/2046 ,  A61K9/00 ,  A61K9/0043 ,  A61K38/17 ,  A61K38/20 ,  A61P11/00 ,  A61P31/16

Abstract: The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.